Related Experiment Video
Updated: Sep 17, 2025
11:13
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.7K
Evodiamine Suppresses Lung Cancer Progression Through Modulating FAK/STAT3/AKT Signaling Pathway.
Wen-Xin Yuan1, Wen Chen2,3,4, Ping Hu2,5
1Department of Ultrasonography, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China.
The American Journal of Chinese Medicine
|June 29, 2025
Summary
Evodiamine, a natural compound, effectively inhibits lung cancer cell growth and migration. It works by targeting key signaling pathways, showing promise as a potential treatment for non-small cell lung cancer (NSCLC).
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Lung cancer poses a significant global health challenge.
- Evodiamine, an alkaloid from *Tetradium ruticarpum*, exhibits anti-tumor properties.
- The precise mechanism of evodiamine's action on lung cancer is not fully understood.
Purpose of the Study:
- To investigate the effects of evodiamine on lung cancer cells.
- To elucidate the underlying molecular mechanisms of evodiamine's anti-cancer activity.
- To evaluate evodiamine's efficacy in preclinical lung cancer models.
Main Methods:
- Cell proliferation and migration assays using A549 and H1299 lung cancer cell lines.
- Western blot analysis to assess protein expression and phosphorylation levels (FAK, STAT3, AKT, CyclinA2, CyclinB1).
- In vivo studies using subcutaneous tumor models in mice.
Main Results:
- Evodiamine significantly suppressed proliferation and migration of A549 and H1299 cells.
- Evodiamine downregulated phosphorylated FAK, STAT3, and AKT, and reduced CyclinA2/B1 expression.
- Evodiamine inhibited EGF-induced FAK/STAT3/AKT phosphorylation and slowed tumor growth in vivo.
Conclusions:
- Evodiamine inhibits non-small cell lung cancer (NSCLC) cell proliferation and migration.
- The mechanism involves downregulation of the EGF-mediated FAK/STAT3/AKT pathway.
- Evodiamine demonstrates potential as a therapeutic agent for NSCLC.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
01:20The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:07MAPK Signaling Cascades
6.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.2K